10 April 2006
RNAi: A novel antisense technology and its therapeutic potential.
Anne Dallas, Alexander V. VlassovMed Sci Monit 2006; 12(4): RA67-74 :: ID: 448934
Abstract
Antisense oligonucleotide agents induce the inhibition of target gene expressionin a sequence-specific manner by exploiting the ability of oligonucleotides to bind to target RNAs viaWatson-Crick hybridization. Once bound, the antisense agent either disables or induces the degradationof the target RNA. This technology may be used for therapeutic purposes, functional genomics, and targetvalidation. There are three major categories of gene-silencing molecules: (1) antisense oligonucleotidederivatives that, depending on their type, recruit RNase H to cleave the target mRNA or inhibit translationby steric hindrance; (2) ribozymes and deoxyribozymes - catalytically active oligonucleotides that causeRNA cleavage; (3) small interfering double-stranded RNA molecules that induce RNA degradation througha natural gene-silencing pathway called RNA interference (RNAi). RNAi is the latest addition to the familyof antisense technologies and has rapidly become the most widely used approach for gene knockdown becauseof its potency. In this mini-review, we introduce the RNAi effect, briefly compare it with existing antisensetechnologies, and discuss its therapeutic potential, focusing on recent animal studies and ongoing clinicaltrials. RNAi may provide new therapeutics for treating viral infections, neurodegenerative diseases,septic shock, macular degeneration, cancer, and other illnesses, although in vivo delivery of small interferingRNAs remains a significant obstacle.
Keywords: Neoplasms - therapy, Neurodegenerative Diseases - therapy, Oligonucleotides, Antisense - genetics, RNA Interference, RNA, Small Interfering - therapeutic use, Virus Diseases - therapy
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
SARS-CoV-2/COVID-19
27 June 2022 : Clinical Research
Shoulder Injury Related to Vaccine Administration (SIRVA) in 16 Patients Following COVID-19 Vaccination Who...Med Sci Monit In Press; DOI: 10.12659/MSM.937430
04 June 2022 : Clinical Research
Screening for SARS-CoV-2 Infection in Students at the Medical University of Warsaw, Poland Between November...Med Sci Monit 2022; 28:e936962
30 May 2022 : Clinical Research
Effects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...Med Sci Monit 2022; 28:e936069
27 May 2022 : Clinical Research
Factors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)Med Sci Monit 2022; 28:e936547
In Press
28 Jun 2022 : Meta-Analysis
Urodynamics in Early Diagnosis of Diabetic Bladder Dysfunction in Women: A Systematic Review and Meta-AnalysisMed Sci Monit In Press; DOI: 10.12659/MSM.937166
28 Jun 2022 : Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Ery...Med Sci Monit In Press; DOI: 10.12659/MSM.936534
28 Jun 2022 : Database Analysis
LINC00963 May Be Associated with a Poor Prognosis in Patients with Cervical CancerMed Sci Monit In Press; DOI: 10.12659/MSM.935070
27 Jun 2022 : Clinical Research
Shoulder Injury Related to Vaccine Administration (SIRVA) in 16 Patients Following COVID-19 Vaccination Who...Med Sci Monit In Press; DOI: 10.12659/MSM.937430
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952